BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Show more...
FAQ
Biolife Solutions 今天的股价是多少?▼
BJX1.F 当前价格为 €18.9 EUR,过去 24 小时上涨了 +5.59%。在图表上更密切关注 Biolife Solutions 股价表现。
Biolife Solutions 的股票代码是什么?▼
根据交易所不同,股票代码可能会有所不同。例如,在 交易所,Biolife Solutions 的股票以代码 BJX1.F 进行交易。
Biolife Solutions 的股价在上涨吗?▼
BJX1.F 股票较上周下跌 -10%,本月下跌 -7.35%,过去一年 Biolife Solutions 下跌 -26.74%。
Biolife Solutions 的市值是多少?▼
今天 Biolife Solutions 的市值为 910M
Biolife Solutions 下一次财报日期是什么时候?▼
Biolife Solutions 将于 三月 12, 2026 发布下一次财报。
Biolife Solutions 上一季度的财报怎么样?▼
BJX1.F 上季度财报为每股 0.01 EUR,预估为 -0.01 EUR,带来 +186.49% 的意外。下季度预估财报为每股 不适用 EUR。
Biolife Solutions 去年的营收是多少?▼
Biolife Solutions 去年的营收为 227.25MEUR。
Biolife Solutions 去年的净利润是多少?▼
BJX1.F 去年的净收益为 -37.8MEUR。
Biolife Solutions 有多少名员工?▼
截至二月 03, 2026,公司共有159名员工。
Biolife Solutions 属于哪个行业?▼
Biolife Solutions从事于Health Care行业。
Biolife Solutions 何时完成拆股?▼
Biolife Solutions 最近没有进行任何拆股。
Biolife Solutions 的总部在哪里?▼
Biolife Solutions 的总部位于 US 的 Bothell。